170 related articles for article (PubMed ID: 28498624)
1. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Chiu PK; Alberts AR; Venderbos LDF; Bangma CH; Roobol MJ
BJU Int; 2017 Sep; 120(3):394-400. PubMed ID: 28498624
[TBL] [Abstract][Full Text] [Related]
2. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
3. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
5. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
6. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
7. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program.
Rietbergen JB; Kruger AE; Kranse R; Schröder FH
Urology; 1997 Jun; 49(6):875-80. PubMed ID: 9187694
[TBL] [Abstract][Full Text] [Related]
8. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
9. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
10. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
11. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Wolters T; Roobol MJ; Bangma CH; Schröder FH
Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
[TBL] [Abstract][Full Text] [Related]
12. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
13. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
14. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
16. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
17. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
Minnee P; Hessels D; Schalken JA; Van Criekinge W
BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
[TBL] [Abstract][Full Text] [Related]
19. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
Raaijmakers R; Kirkels WJ; Roobol MJ; Wildhagen MF; Schrder FH
Urology; 2002 Nov; 60(5):826-30. PubMed ID: 12429309
[TBL] [Abstract][Full Text] [Related]
20. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
